Clinical Trial Update: Phase II Study of REPotrectinib With or Without Fulvestrant in Patients With Hormone Receptor-positive Human Epidermal Growth Factor 2-negative Metastatic Invasive LObular Carcinoma Who Received a Prior Endocrine Therapy in Combination With Cyclin-dependent Kinase 4 and 6 Inhibitor (REPLOT Trial) [Phase 2]

View source ↗

Summary

Phase II study of repotrectinib with or without fulvestrant in hormone receptor-positive, HER2-negative metastatic invasive lobular breast cancer (after prior e…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hormone Receptor-positive Metastatic Invasive Lobular Breast Cancer

Drugs mentioned

• Fulvestrant (fulvestrant)
• Repotrectinib (repotrectinib)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Hormone Receptor-positive Human Epidermal Growth Factor 2-negative, Metastatic Invasive LObular Carcinoma | Phase 2 | Status: TERMINATED